Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Houria Debarri"'
Autor:
Pierre-Yves Dumas, Emmanuel Raffoux, Emilie Bérard, Sarah Bertoli, Marie-Anne Hospital, Maël Heiblig, Yohann Desbrosses, Caroline Bonmati, Cécile Pautas, Juliette Lambert, Corentin Orvain, Anne Banos, Florence Pasquier, Pierre Peterlin, Tony Marchand, Madalina Uzunov, Jamilé Frayfer, Pascal Turlure, Thomas Cluzeau, Eric Jourdan, Chantal Himberlin, Emmanuelle Tavernier, Alban Villate, Stephanie Haiat, Marie-Lorraine Chretien, Martin Carre, Sylvain Chantepie, Ioana Vaida, Mathieu Wemeau, Safia Chebrek, Gaelle Guillerm, Romain Guièze, Houria Debarri, Eve Gehlkopf, Kamel Laribi, Ambroise Marcais, Alberto Santagostino, Marie-Christine Béné, Ariane Mineur, Arnaud Pigneux, Hervé Dombret, Christian Récher
Publikováno v:
Leukemia.
The real-world efficacy and safety of gilteritinib was assessed in an ambispective study that included 167 R/R FLT3-mutated AML patients. Among them, 140 received gilteritinib as single agent (cohort B), including 67 previously treated by intensive c
Autor:
Olivier Tournilhac, Matthew S. Davids, Sorin Visanica, Franck Morschhauser, Abderrazak El Yamani, Sophie Godet, Charles Herbaux, Stéphanie Poulain, Hugo Gonzalez, Loic Ysebaert, François Lemonnier, Damien Roos-Weil, Maxime Jullien, Jérôme Moreaux, Houria Debarri, Yann Guillermin, Jacques-Olivier Bay, Kamel Laribi
Publikováno v:
Blood. 138:1201-1201
Background: Ruxolitinib (RUX), a JAK1/JAK2 inhibitor, and venetoclax (VEN), a BCL-2 inhibitor are 2 drug candidates recently identified as promising candidate for the treatment of T-Cell prolymphocytic leukemia (T-PLL). We recently reported that JAK/
Autor:
Loïc Renaud, Jean-Baptiste Bossard, Zoé Van de Wyngaert, Sarah Barbieux, Alexandre Willaume, Guillaume Escure, Claire Bories, Bruno Quesnel, Serge Alfandari, Marie Titecat, Morgane Nudel, Céline Berthon, Sarah Bonnet, Benjamin Carpentier, Houria Debarri, Paul Chauvet, Ines Arib, Nicolas Branche, Arthur Simonnet, Kevin James Wattebled, Charline Legrand
Publikováno v:
International Journal of Antimicrobial Agents
International Journal of Antimicrobial Agents, 2019, 53, pp.781-788. ⟨10.1016/j.ijantimicag.2019.02.020⟩
International Journal of Antimicrobial Agents, 2019, 53, pp.781-788. ⟨10.1016/j.ijantimicag.2019.02.020⟩
Objectives Antibiotics for febrile neutropenia (FN) in acute myeloid leukaemia (AML) patients undergoing intensive chemotherapy are usually maintained until neutropenia resolution, because of the risk of uncontrolled sepsis in this vulnerable populat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc10918ec26fb206ab34342a2c85606
https://hal.archives-ouvertes.fr/hal-03484940/file/S0924857919300500.pdf
https://hal.archives-ouvertes.fr/hal-03484940/file/S0924857919300500.pdf
Autor:
Guillemette Fouquet, Stéphanie Tardy, Hélène Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Stéphanie Guidez, Jessica Michel, Aurore Perrot, Caroline Serrier, Darko Miljkovic, Hervé Avet Loiseau, Thierry Facon, Cyrille Hulin, Xavier Leleu
Publikováno v:
Cancer. 119:3680-3686
BACKGROUND: Lenalidomide in combination with dexamethasone (Len=Dex) is indicated for patients with recurrent=refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression. The objective of the current
Publikováno v:
Bulletin du Cancer. 100:775-779
Brentuximab vedotin is a new antibody-drug conjugate composed of the anti-CD30 chimeric monoclonal antibody and the potent antimicrotubule drug monomethylauristatin E. In two phase II clinical trials, treatment with single-agent brentuximab vedotin r
Publikováno v:
British journal of haematology. 163(2)
Publikováno v:
Bulletin du cancer. 100(7-8)
Brentuximab vedotin is a new antibody-drug conjugate composed of the anti-CD30 chimeric monoclonal antibody and the potent antimicrotubule drug monomethylauristatin E. In two phase II clinical trials, treatment with single-agent brentuximab vedotin r
Autor:
Guillemette, Fouquet, Stéphanie, Tardy, Hélène, Demarquette, Sarah, Bonnet, Julie, Gay, Houria, Debarri, Charles, Herbaux, Stéphanie, Guidez, Jessica, Michel, Aurore, Perrot, Caroline, Serrier, Darko, Miljkovic, Hervé, Avet Loiseau, Thierry, Facon, Cyrille, Hulin, Xavier, Leleu
Publikováno v:
Cancer. 119(20)
Lenalidomide in combination with dexamethasone (Len/Dex) is indicated for patients with recurrent/refractory multiple myeloma (RRMM) who were treated with 1 prior therapy until evidence of disease progression. The objective of the current study was t
Autor:
Sophie, Dupire, Mathieu, Wemeau, Houria, Debarri, Laurent, Pascal, Benedicte, Hivert, Christophe, Willekens, Eileen, Boyle, Salomon, Manier, Thielemans, Béatrice, Brigitte, Onraed, Jean-Luc, Faucompré, Bernadette, Hennache, Charles, Dumontet, Thierry, Facon, Xavier, Leleu
Publikováno v:
European journal of haematology. 88(4)
The Prognostic Inflammatory and Nutritional Index (PINI) is a simple scoring system that aggregates two blood markers of inflammatory [C-reactive protein (CRP) and orosomucoid] and of nutritional (albumin and prealbumin) states. It is used in routine
Autor:
Guillemette Fouquet, Stéphanie Tardy, Helene Demarquette, Sarah Bonnet, Julie Gay, Houria Debarri, Charles Herbaux, Jessica Michel, Aurore Perrot, Caroline Serrier, Suzanne K. Robinson, Darko Miljkovic, Pascale Morel, Catherine Boccacio, Herve AvetLoiseau, Thierry Facon, Cyrille Hulin, Xavier Leleu
Publikováno v:
Blood. 120:2964-2964
Abstract 2964 Background. Lenalidomide is an oral IMiD®, immunomodulatory compound, approved for use in combination with dexamethasone (Len/Dex) in patients with RRMM who have received one prior therapy. Len/Dex is indicated until evidence of diseas